Check for updates





Blood 142 (2023) 571-575

The 65th ASH Annual Meeting Abstracts

ORAL ABSTRACTS

508.BONE MARROW FAILURE: ACQUIRED

Factor B Inhibition with Oral Iptacopan Monotherapy Demonstrates Sustained Long-Term Efficacy and Safety in Anti-C5-Treated Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) and Persistent Anemia: Final 48-Week Results from the Multicenter, Phase III APPLY-PNH Trial Antonio M Risitano, MDPhD^{1,2}, Austin Kulasekararaj, MD PhD MPH^{3,4,5}, Alexander Roeth, MD⁶, Phillip Scheinberg, MD⁷, Yasutaka Ueda⁸, Carlos de Castro⁹, Eros Di Bona¹⁰, Morag Griffin, FRCPath,MRCP¹¹, Saskia MC Langemeijer, MD PhD¹², Hubert Schrezenmeier, MD^{13,14}, Wilma Barcellini, MD¹⁵, Vitor AQ Mauad, MD¹⁶, Jens Panse, MD^{17,18}, Philippe Schafhausen¹⁹, Suzanne Tavitian, MD²⁰, Eloise Beggiato²¹, Anna Gaya²², Wei-Han Huang²³, Toshio Kitawaki, MD²⁴, Abdullah Kutlar, MD²⁵, Jaroslaw P. Maciejewski, MD, PhD, FACP²⁶, Rosario Notaro^{27,28}, Vinod Pullarkat, MD²⁹, Jörg Schubert³⁰, Louis Terriou, MD³¹, Michihiro Uchiyama³², Flore Sicre De Fontbrune³³, Camilla Frieri^{1,2}, Ferras Alashkar⁶, Shreyans Gandhi³, Rakesh Kumar³⁴, Christine Thorburn³⁵, Samopriyo Maitra³⁴, Susan Solar-Yohay³⁶, Tomasz Lawniczek³⁷, Marion Dahlke, MD³⁷, Régis Peffault De Latour^{38,33} ¹AORN Moscati, Avellino, Italy ²University of Naples Federico II, Naples, Italy ³King's College Hospital NHS, London, United Kingdom ⁴National Institute for Health and Care Research and Wellcome King's Research Facility, London, United Kingdom ⁵ King's College London, London, United Kingdom ⁶West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany ⁷ Hospital A Beneficência Portuguesa, São Paulo, Brazil ⁸Osaka University Graduate School of Medicine, Suita, Japan ⁹ Duke University School of Medicine, Durham, NC ¹⁰UOC Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (VI), Vicenza, Italy ¹¹ St James's University Hospital, Leeds, United Kingdom ¹²Radboud University Medical Center, Nijmegen, Netherlands ¹³University of Ulm, Ulm, Germany ¹⁴German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen and University Hospital Ulm, Ulm, Germany ¹⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy ¹⁶ABC Medical School, Santo André, Brazil ¹⁷University Hospital RWTH Aachen, Aachen, Germany ¹⁸Center for Integrated Oncology (CIO) Aachen Bonn Cologne Düsseldorf, Aachen, Germany ¹⁹ Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany ²⁰Centre Hospitalo-Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'Hématologie, Toulouse, France ²¹University of Torino, Turin, Italy ²²Hospital Clinic of Barcelona, Barcelona, Spain ²³Hualien Tzu Chi Hospital, Hualien, Taiwan ²⁴ Kyoto University, Kyoto, Japan ²⁵Department of Medicine, Medical College of Georgia, Augusta, GA ²⁶Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH ²⁷ Azienda Ospedaliera Universitaria Careggi, Firenze, Italy ²⁸Instituto per lo Studio, la Prevenzione e la Rete Oncologica, Firenze, Italy ²⁹City of Hope National Medical Center, Duarte, CA ³⁰Elblandklinikum Riesa, Riesa, Germany ³¹CHU Lille, Université de Lille, Lille, France ³² Japanese Red Cross Society Suwa Hospital, Suwa, Japan

ORAL ABSTRACTS

³³ French Référence Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Paris, France

³⁴Novartis Healthcare Private Limited, Hyderabad, India

³⁵Novartis Pharmaceuticals UK Limited, London, United Kingdom

³⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

³⁷ Novartis Pharma AG, Basel, Switzerland

³⁸Assistance Publique Hôpitaux de Paris, Université Paris Cité, Paris, France

Drs Roeth and Kulasekararaj contributed equally as authors.

Background: Iptacopan is the first oral complement inhibitor that acts proximally in the complement system to target factor B in the alternative pathway. Iptacopan has shown efficacy/safety in PNH pts with persistent anemia despite anti-C5 therapy and complement inhibitor-naive pts. In the Phase III APPLY-PNH trial (NCT04558918), iptacopan monotherapy led to clinically meaningful hemoglobin (Hb) increases and normal/near-normal Hb levels in a majority of pts, transfusion avoidance and improved pt-reported fatigue, showing superiority vs C5 inhibitors at Week (Wk) 24.

Aim: We report the final APPLY-PNH data after a 24-wk extension period in which all pts received iptacopan monotherapy (study completion: 6 March 2023).

Methods: Adult PNH pts (mean Hb <10 g/dL, receiving anti-C5 therapy for \geq 6 months) were randomized to receive iptacopan 200 mg twice daily or continue their anti-C5 regimen for 24 wks. Pts could then opt to enter an extension period; pts in the iptacopan arm received iptacopan for another 24 wks and pts who had been receiving anti-C5 switched to iptacopan monotherapy.

Results: In the extension period, 95 pts received iptacopan: 61/62 in the iptacopan arm (1 discontinued iptacopan in the randomized period because of pregnancy) and 34/35 in the anti-C5-to-iptacopan arm (1 did not enter the extension period [investigator's decision]). In the iptacopan arm, the improvements at 24 wks were sustained at 48 wks, with maintenance of increased Hb, normal/near-normal mean Hb levels (Figure), improved Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scores, decreased absolute reticulocyte counts (ARCs) and transfusion avoidance (Table). Pts who switched from anti-C5 to iptacopan had rapid changes in Hb, FACIT-F and ARC, achieving comparable improvements to the iptacopan arm. Mean Hb levels at Wk 48 were 12.2 and 12.1 g/dL in the iptacopan and anti-C5-to-iptacopan arms, respectively (standard deviations 1.6 and 1.4). At Wk 48, the adjusted mean change from baseline in the iptacopan arm was +3.35 g/dL for Hb, +9.80 FACIT-F points and -106.26×10^{9} /L for ARC. In the anti-C5-to-iptacopan arm, the adjusted mean change from baseline at Wk 48 was +3.36 g/dL for Hb, +10.96 FACIT-F points and -107.95×10^{9} /L for ARC (adjusted mean difference in change from baseline at Wk 48 vs Wk 24: +3.02 g/dL, +10.79 points and -102.29×10^{9} /L, respectively). Transfusion avoidance was achieved by 93.5% of pts in the iptacopan arm (Wks 2 to 48) and 94.1% in the anti-C5-to-iptacopan arm (Wks 26 to 48). Mean lactate dehydrogenase levels were generally maintained <1.5 × upper limit of normal in both arms.

In the trial, 6/62 pts in the iptacopan arm had clinical breakthrough hemolysis (BTH). One pt in the anti-C5-to-iptacopan arm had clinical BTH after switching to iptacopan. BTH resolved without changing iptacopan dosing. Three pts had major adverse vascular events (MAVEs; randomized period: 1 serious transient ischemic attack [TIA]; extension period: 1 non-serious TIA, 1 serious portal vein thrombosis [PVT]). The pt with PVT had a history of PVT and discontinued heparin prior to the MAVE. All MAVEs were considered unrelated to iptacopan and resolved without changing iptacopan dosing. After 48 wks in the iptacopan arm, the most frequently reported treatment-emergent adverse events (TEAEs) were COVID-19 (29.0% of pts), headache (19.4%), diarrhea (16.1%) and nasopharyngitis (14.5%). There were no deaths, no serious hemolysis TEAEs on iptacopan, no serious infections caused by *N. meningitidis, S. pneumoniae* or *H. influenzae* and no pts discontinued treatment because of TEAEs.

Conclusions: Long-term data from the Phase III APPLY-PNH trial show a durable response to iptacopan monotherapy in anti-C5-treated PNH pts with persistent anemia. Pts who received iptacopan for 48 wks had sustained improvements in multiple hematological and clinical outcomes, including maintenance of increased Hb, mean normal/near-normal Hb levels, transfusion avoidance and decreased pt-reported fatigue; these benefits quickly emerged in the anti-C5-to-iptacopan arm, supporting the benefit of switching from C5 inhibitors to iptacopan monotherapy. The data indicate good control of hemolysis by iptacopan and a similar safety profile at Wk 48 vs Wk 24. Our findings continue to support oral iptacopan monotherapy as a potentially practice-changing treatment for hemolytic PNH.

Disclosures Risitano: Novartis: Consultancy, Honoraria; F. Hoffmann-La Roche Ltd: Consultancy, Honoraria, Research Funding; Alexion, AstraZeneca Rare Disease: Consultancy, Honoraria, Research Funding. **Kulasekararaj:** Alexion, AstraZeneca Rare Disease: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Akari Therapeutics: Consultancy; Celgene/BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche Ltd: Consultancy, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees; BioCryst: Consultancy; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BioCryst: Consultancy; Samsung: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Research Funding; BioCryst: Consultancy, Research Funding; Novartis: Consultancy, Other: Scientific presentations, Research Funding, Speakers Bureau; Alexion: Consultancy, Other: Scientific presentations, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer: Consultancy, Other: Speaker, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer: Consultancy, Other: Speaker, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer: Consultancy, Other: Speaker, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer: Consultancy, Other: Speaker, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer: Consultancy, Other: Speaker, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer: Consultancy, Other: Speaker, Research Funding; F. Hoffmann-La Roche Ltd; Consultancy, Other: Speaker; Pfizer:

ORAL ABSTRACTS


Consultancy, Other: Scientific presentations, Research Funding; Amgen: Consultancy, Other: Scientific presentations/speaker; AstraZeneca: Consultancy, Other: Scientific presentations/speaker, Research Funding; Janssen: Consultancy, Other: Scientific presentations/speaker; AbbVie: Consultancy, Other: Speaker; Alnylam: Research Funding; BMS: Other: Speaker; Viracta: Research Funding. Ueda: Asahi Kase: Consultancy; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Chugai: Consultancy, Honoraria, Research Funding; Janssen: Consultancy; Alexion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SOBI: Consultancy, Honoraria. de Castro: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Biocryst: Honoraria; Apellis: Consultancy, Speakers Bureau; Alexion: Consultancy, Speakers Bureau; Omeros: Honoraria; Regeneron: Honoraria. Di Bona: Alexion: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees. Griffin: Amgen: Membership on an entity's Board of Directors or advisory committees; Biocryst: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Regeneron Pharmaceuticals: Consultancy; Sobi: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Alexion, AstraZeneca Rare Disease: Honoraria, Membership on an entity's Board of Directors or advisory committees; Apellis: Other: educational grant support . Schrezenmeier: Roche: Other: honoraria (to University of Ulm); Apellis: Other: honoraria (to University of Ulm); Sobi: Honoraria, Other: travel support, Research Funding; Novartis: Honoraria, Other: travel support, Research Funding; Alexion, AstraZeneca Rare Disease: Honoraria, Other: travel support, Research Funding; Sanofi: Other: honoraria (to University of Ulm). Barcellini: Novartis: Consultancy, Honoraria, Speakers Bureau; Alexion, AstraZeneca Rare Disease: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Panse: Blueprint Medicines: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy; Sanofi Ltd: Consultancy; BMS: Consultancy; Apellis Pharmaceuticals, Inc.: Consultancy; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Consultancy; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; F. Hoffmann-La Roche Ltd,: Membership on an entity's Board of Directors or advisory committees, Other: Third party writing assistance by Akshaya Srinivasan, PhD, of MediTech Media Ltd and funded by F. Hoffmann-La Roche Ltd, , Speakers Bureau; SOBI: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Alexion, AstraZeneca Rare Disease: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Samsung Bioepis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Schafhausen: Sobi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Merck Serono: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; BMS/Celgene: Consultancy, Honoraria, Other: Travel and accomodation support; Blueprint Medicines Corporation: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; AOP Orphan: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support; Alexion: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel and accomodation support. Tavitian: Servier: Membership on an entity's Board of Directors or advisory committees; Incyte: Other: Webinar; Novartis: Membership on an entity's Board of Directors or advisory committees. Gaya: SOBI: Honoraria, Other: Lectures, educational activities; Novartis: Honoraria, Other: Lectures, educational activities; Alexion: Honoraria, Other: Lectures, educational activities; Roche: Honoraria, Other: Lectures, educational activities. Huang: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Chugai: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Kitawaki: Novartis: Other: lecture. Kutlar: GBT/Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Forma/Novo-Nordisk, Akira Bio: Research Funding; Bluebird Bio: Membership on an entity's Board of Directors or advisory committees; Vertex: Other: Event adjudication committee (EAC) Chair. Maciejewski: Regeneron: Consultancy, Honoraria; Alexion: Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Speakers Bureau; Omeros: Consultancy. Notaro: SAMSUNG BIOEPIS: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Alexion: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SOBI: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Pullarkat: Novartis: Consultancy, Speakers Bureau; Genentech: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Servier: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Jazz Pharmaceuticals: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Schubert: Alexion: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Sobi: Consultancy, Honoraria. Terriou: Sobi: Honoraria; Alexion: Honoraria; Eusapharma: Consultancy. Sicre De Fontbrune: Alexion, AstraZeneca Rare Disease: Honoraria, Research Funding; Sobi: Honoraria, Research Funding; Samsung: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Alashkar: Agios: Speakers Bureau; Global Blood

ORAL ABSTRACTS

Session 508

Therapeutics: Consultancy, Honoraria, Research Funding, Speakers Bureau; Bristol Myers Squibb/Celgene: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau. **Gandhi:** Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; SOBI: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Alexion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Honoraria, Speakers Bureau. **Kumar:** Novartis: Current Employment, Current equity holder in publicly-traded company. **Thorburn:** Novartis: Current Employment. **Maitra:** Novartis: Current Employment, Current equity holder in publicly-traded company. **Solar-Yohay:** Novartis: Current Employment, Current equity holder in publicly-traded company. **Lawniczek:** Novartis: Current Employment, Current equity holder in publicly-traded company. **Lawniczek:** Novartis: Current Employment, Current equity holder in publicly-traded company. Honoraria, Research Funding; Gilead: Consultancy, Honoraria; MSD: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Keocyte: Consultancy, Honoraria; Jazz: Consultancy, Honoraria, Research Funding; Samsung: Consultancy, Honoraria; Roche: Consultancy, Honoraria; SOBI: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding.

Figure. Mean Hb level (SD) over time during the entire 48-week treatment period of APPLY-PNH



Includes post-transfusion data. At Week 25, Hb data were only available for 1 pt in the iptacopan arm (Hb level: 13.9 g/dL); this was not a scheduled visit in the protocol for the iptacopan arm but was for the anth-C5-to-iptacopan arm. The value in the iptacopan arm is not plotted on the graph as 1 pt cannot be representative of the whole treatment group BL, baseline; Hb, hemoglobin; pt, patient; SD, standard deviation

Table. Summary of efficacy parameters after the entire 48-week treatment period of APPLY-PNH, including comparison of data at Week 48 vs Week 24

Parameter	Arm					
	lptacopan N=62 Anti-C5 to iptacopan N=3	6	djusted mean change om baseline (95% Cl at Week 48		Adjusted mean difference in change from baseline (95% Cl): Week 48 vs Week 24	
Change from baseline* in Hb level (g/dL) [†]	Iptacopan	+3.35 (3.03, 3.66)			-0.41 (-0.80, -0.01)	
	Anti-C5 to iptacopan	+3.36 (2.93, 3.79)			+3.02 (2.48, 3.56)	
Change from baseline [‡] in FACIT-F score	Iptacopan		+9.80 (8.04, 11.56)		+0.73 (-1.14, 2.60)	
	Anti-C5 to iptacopan	+10.96 (8.58, 13.34)		+10.79 (8.12, 13.47)		
Change from baseline [§] in ARC (10 ⁹ /L)	Iptacopan	-1	-106.26 (-117.57, -94.96)		+9.92 (-4.40, 24.25)	
	Anti-C5 to iptacopan	-107.95 (-123.18, -92.73)		-102.29 (-121.57, -83.02)		
			ometric adjusted mean paseline (95% CI) at Week 48		Geometric adjusted mean ratio (95% Cl): Week 48 vs Week 24	
Ratio to baseline ¹ in log-transformed LDH (U/L)	Iptacopan		1.11 (1.02, 1.22)		1.12 (1.00, 1.25)	
	Anti-C5 to iptacopan		0.99 (0.88, 1.11)		0.99 (0.85, 1.15)	
		Time period			transfusion since pan monotherapy (n [%])	
Transfusion avoidance [¶]	Iptacopan	Week 2 to Week 48	58 (93.5)			
	Anti-C5 to iptacopan	Week 26 to Week 48 (iptacopan)	32 (94.1)**			
		Time period	n/N‡‡	since initi	djusted annualized rate of events ation of iptacopan monotherapy, g both treatment arms (95% Cl)	
Rate of clinical BTH ^{tt}	Iptacopan	Baseline to Week 48	6/62		- 0.11 (0.05, 0.23)	
	Anti-C5 to iptacopan	Week 24 to Week 48 (iptacopan)	1/34			
Rate of MAVEs	Iptacopan	Baseline to Week 48	2/62		- 0.04 (0.01, 0.13)	
	Anti-C5 to iptacopan	Week 24 to Week 48 (iptacopan)	1/34			

*Mean (SD) baseline Hb levels were 8.93 (0.70) and 8.85 (0.90) g/dL in the iptacopan and anti-C5-to-iptacopan arms, respectively; 'Analysis includes all central lab Hb data, including post-transfusion data; 'Mean (SD) baseline FACIT-F scores were 34.7 (9.8) and 30.8 (11.5) in the iptacopan and anti-C5-to-iptacopan arms, respectively; 'Mean (SD) baseline FACIT-F scores were 34.7 (9.8) and 30.8 (11.5) in the iptacopan and anti-C5-to-iptacopan arms, respectively; 'Mean (SD) baseline LDH levels were 269.1 (70.1) and 272.7 (84.8) U/L in the iptacopan arms, respectively; 'Defined as neither receiving nor meeting the criteria to receive an RBC transfusion; "'34 of 35 patients in the anti-C5-to-iptacopan arm (respectively); 'Defined as neither receiving nor meeting the criteria to receive an RBC transfusion; "'34 of 35 patients in the anti-C5-to-iptacopan arm (respectively); 'Defined as neither receiving nor meeting the criteria to receive an RBC transfusion; "'34 of 35 patients in the anti-C5-to-iptacopan arm (respectively); 'Defined as neither receiving nor meeting the criteria to receive an RBC transfusion; "'34 of 35 patients in the anti-C5-to-iptacopan arm (received iptacopan arm (received iptacopan ACC, the count; "HL, breakthrough hemolysis; C1, confidence interval; FACIT-F, Functional Assessment of Chronic Illness Therapy – Fatigue; Hb, hemoglobin; LDH, lactate dehydrogenase; MAVE, major adverse vascular event; pt, patient; RBC, red blood cell; SD, standard deviation

Figure 1

https://doi.org/10.1182/blood-2023-180780